KIT is an inclusion eligibility criterion in 2 clinical trials for systemic mastocytosis, of which 2 are open and 0 are closed. Of the trials that contain KIT status and systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (1 open) [3].

MECOM is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and systemic mastocytosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and systemic mastocytosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and systemic mastocytosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and systemic mastocytosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].